Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing

Aligos Therapeutics, Inc.

Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.
Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.
Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.
ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.
James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.